Volume 7 Issue 6
Nov.  2016
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2016  >  7(6): 459-462
Zhang Ling, Zhang Xiangzhong, Li Xiaoqing, et al. Clinical efficacy of umbilical cord-derived menchymal stem cell treatment of refractory chronic graft-versus-host disease[J]. ORGAN TRANSPLANTATION, 2016, 7(6): 459-462. doi: 10.3969/j.issn.1674-7445.2016.06.009
Citation: Zhang Ling, Zhang Xiangzhong, Li Xiaoqing, et al. Clinical efficacy of umbilical cord-derived menchymal stem cell treatment of refractory chronic graft-versus-host disease[J]. ORGAN TRANSPLANTATION, 2016, 7(6): 459-462. doi: 10.3969/j.issn.1674-7445.2016.06.009
shu

Clinical efficacy of umbilical cord-derived menchymal stem cell treatment of refractory chronic graft-versus-host disease

doi: 10.3969/j.issn.1674-7445.2016.06.009

  • Department of Hematology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Li Xudong. E-mail:13631359815@139.com.
  • Received Date: 2016-08-16
    Available Online: 2021-03-19
  • Publish Date: 2016-11-15
    Abstract
  •   Objective   To evaluate the clinical efficacy and safety of umbilical cord-derived mesenchymal stem cell (MSC) treatment of refractory chronic graft-versus-host disease (cGVHD) after allogene hematopoietic stem cell transplantation.   Methods   Seven patients developed with cGVHD following allogene hematopoietic stem cell transplantation. Conventional immunosuppressive agent treatment yielded no efficacy. Based upon immunosuppressive agent therapy, umbilical cord-derived MSC treatment was supplemented with a cell density of 1×106/kg, once a week for consecutive 4 times. Clinical efficacy, safety and survival of the patients were observed.   Results   Among 7 patients receiving MSC injection, 2 obtained complete response (CR) and 3 had partial response (PR) with an overall response rate of 5/7, and the remaining 2 cases achieved no response (NR). No adverse reactions were induced by MSC injection. No patient had primary disease recurrence. One patient developed secondary cytomegalovirus pneumonia after PR and died from severe pneumonia. The remaining patients survived.   Conclusions   Umbilical cord -derived MSC injection is an efficacious and safe therapy of cGVHD.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research[J]. Biol Blood Marrow Transplant, 2015, 21(2): 266-274. doi: 10.1016/j.bbmt.2014.10.021
    [2]
    Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study[J]. Int J Hematol, 2012, 95(2):182-188. doi: 10.1007/s12185-011-0989-2
    [3]
    Gao F, Chiu SM, Motan DA, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects[J]. Cell Death Dis, 2016,7: e2062. doi: 10.1038/cddis.2015.327
    [4]
    Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅳ. the 2014 Response Criteria Working Group report[J]. Biol Blood Marrow Transplant, 2015, 21(6): 984-999. doi: 10.1016/j.bbmt.2015.02.025
    [5]
    Le Blanc K, Rasmusson I, Sunberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells[J]. Lancet, 2004, 363 (9419): 1439-1441. doi: 10.1016/S0140-6736(04)16104-7
    [6]
    Liu JJ, Li D, Ju X, et al. Umbilical cord-derived mesenchymal stem cells retain immunomodulatory and anti-oxidative activities after neural induction[J]. Neural Regen Res, 2012, 7(34): 2663-2672. http://cn.bing.com/academic/profile?id=1510063224&encoded=0&v=paper_preview&mkt=zh-cn
    [7]
    Zhou J, Tian G, Wang J, et al. Neural cell injury microenvironment induces neural differentiation of human umbilical cord mesenchymal stem cells[J]. Neural Regen Res, 2012, 7(34): 2689-2697.
    [8]
    孙燕玲，李旭东，林东军，等. 非血缘脐血移植治疗高危急性白血病的临床研究[J]. 器官移植, 2015, 6(6): 420-424. http://www.organtranspl.com/browse/detail/qkid/89/id/150.html

    YL, Li XD, Lin DJ, et al. Clinical study on treatment of high-risk acute leukemia with unrelated cord blood transplantation[J]. Organ Transplant, 2015, 6(6): 420-424. http://www.organtranspl.com/browse/detail/qkid/89/id/150.html
    [9]
    Gao L, Zhang Y, Hu B, et al. Phase Ⅱ multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation[J]. J Clin Oncol, 2016, 34 (24): 2834-2850. http://cn.bing.com/academic/profile?id=2460851798&encoded=0&v=paper_preview&mkt=zh-cn
    [10]
    Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase Ⅰ study on 40 adult and pediatric patients[J]. Biol Blood Marrow Transplant, 2014, 20(3) 375-381. doi: 10.1016/j.bbmt.2013.11.033
    [11]
    黄英丹，肖翠容，林进宗，等. 脐带来源间充质干细胞治疗异基因造血干细胞移植后慢性移植物抗宿主病[J]. 中国组织工程研究，2014, 18(50): 8093-8097. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201450012.htm

    Huang YD, Xiao CR, Lin JZ, et al. Treatment of chronic graft-versus-host disease with human umbilical cord mesenchymal stem cells[J]. Chin J Tissue Eng Res, 2014,18 (50): 8093- 8097. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201450012.htm
    [12]
    卢荣标，陆春. 移植物抗宿主疾病皮肤损害的治疗进展[J]. 器官移植, 2013 , 4 (3) : 169-176. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201303012.htm

    Lu RB, Lu C. Therapeutic advance in cutaneous graft-versus-host disease[J]. Organ Transplant,2013,4(3):169-176. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201303012.htm
    [13]
    Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD[J]. Bone Marrow Trasplant, 2010, 45(12): 1732-1740. doi: 10.1038/bmt.2010.195
    [14]
    Lazarus HM, Pavletic SZ. Umbilical cord blood-derived mesenchymal stromal cells for reducing chronic graft-versus-host disease after haploidentical transplantation: just another labor-intensive strategy, or showing the way?[J]. J Clin Oncol, 2016, 34 (24): 2812-2813. doi: 10.1200/JCO.2016.67.7344
    [15]
    Kim N, Im KI, Lim JY, et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice[J]. Ann Hematol, 2013, 92(10): 1295-1308. doi: 10.1007/s00277-013-1796-z
    [16]
    Kuzmina LA, Petinati NA, Parovichnikova EN, et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease-a phase Ⅱ study[J]. Stem Cells Int, 2012: 968213. http://cn.bing.com/academic/profile?id=2126957024&encoded=0&v=paper_preview&mkt=zh-cn
    [17]
    Liu K, Chen Y, Zeng Y, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study[J]. Stem Cells Dev, 2011, 20(10): 1679-1685. doi: 10.1089/scd.2010.0447
    [18]
    Zhao K, Lou R, Huang F, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(1): 97-104. doi: 10.1016/j.bbmt.2014.09.030
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (278) PDF downloads(13) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return